{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T23:35:30Z","timestamp":1788478530510,"version":"build-2803163510"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T00:00:00Z","timestamp":1654214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Immune checkpoint inhibitors (ICIs) have now become the standard therapy for malignancies like non-small cell lung cancer and classical Hodgkin\u2019s lymphoma. ICIs are associated with unique immune-related adverse events (irAEs) caused by dysregulated immune activation. Treatment of lower gastrointestinal (GI) tract irAEs, such as colitis, is more common. However, for upper gastrointestinal tract irAEs, there is a lack of consensus in terms of globally standardized disease classification and treatment guidelines. Here, we report a case of sintilimab-induced acute erosive hemorrhagic gastritis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case Presentation<\/jats:title><jats:p>A 54-year-old man with metastatic NSCLC (PT2N2M1 stage IV) underwent treatment with eight courses of sintilimab + bevacizumab, followed by maintenance therapy with sintilimab alone. However, he presented with epigastric pain and melena at the end of the first sintilimab treatment, and the symptoms occurred repeatedly after regular treatment with acute erosive hemorrhagic gastritis. Repeat esophagogastroduodenoscopy (EGD) showed severe hemorrhagic gastritis; symptomatic relief and improvement in EGD images were noted for as long as he was being treated with steroids, methylprednisolone sodium.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>As far as we are aware, we here describe the first case of sintilimab-associated acute erosive hemorrhagic gastritis, an upper gastrointestinal toxicity event. Throughout the treatment progression, differential diagnosis, multidisciplinary discussion, and the use of immunosuppressants were instrumental in clarifying the diagnosis and were crucial to the prognosis of the patient and continued treatment with ICIs.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2022.840916","type":"journal-article","created":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T10:00:34Z","timestamp":1654250434000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Upper Gastrointestinal Tract IrAEs: A Case Report About Sintilimab-Induced Acute Erosive Hemorrhagic Gastritis"],"prefix":"10.3389","volume":"13","author":[{"given":"Qi","family":"Ai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonggui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-Related Adverse Events of Checkpoint Inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) Clinical Practice Guideline on Immune Checkpoint Inhibitor-Related Adverse Events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(18)30192-3","article-title":"Safety and Activity of Sintilimab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (ORIENT-1): A Multicentre, Single-Arm, Phase 2 Trial","volume":"6","author":"Shi","year":"2019","journal-title":"Lancet Haematol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1080\/00365521.2019.1594356","article-title":"Upper Gastrointestinal Symptoms and Associated Endoscopic and Histological Features in Patients Receiving Immune Checkpoint Inhibitors","volume":"54","author":"Tang","year":"2019","journal-title":"Scand J Gastroenterol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2020-0070-RA","article-title":"Pathologic Manifestations of Gastrointestinal and Hepatobiliary Injury in Immune Checkpoint Inhibitor Therapy","volume":"145","author":"Patil","year":"2021","journal-title":"Arch Pathol Lab Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse Effects of Immune-Checkpoint Inhibitors: Epidemiology, Management and Surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ctrv.2019.03.004","article-title":"Choosing Wisely First Line Immunotherapy in Non-Small Cell Lung Cancer (NSCLC): What to Add and What to Leave Out","volume":"75","author":"Proto","year":"2019","journal-title":"Cancer Treat Rev"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.07.014","article-title":"Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: A Randomized, Double-Blind, Phase 3 Study (Oncology Program by InnovENT Anti-PD-1-11)","volume":"15","author":"Yang","year":"2020","journal-title":"J Thorac Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jtho.2016.10.003","article-title":"The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC","volume":"12","author":"Manegold","year":"2017","journal-title":"J Thorac Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"dju393","DOI":"10.1093\/jnci\/dju393","article-title":"New Therapy Targets Resistant Non-Small-Cell Lung Cancers","volume":"106","author":"Jenks","year":"2014","journal-title":"J Natl Cancer Inst 106"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13569","article-title":"Unexpected Favorable Outcome to Sintilimab Plus Bevacizumab in an EGFR-Mutated Non-Small Cell Lung Cancer Patient: A Case Report","volume":"11","author":"Zhang","year":"2020","journal-title":"Thorac Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.3056","article-title":"A Phase 1 Study of Ramucirumab (R) Plus Pembrolizumab (P) in Patients (Pts) With Advanced Gastric or Gastroesophageal Junction (G\/GEJ) Adenocarcinoma, Non-Small Cell Lung Cancer (NSCLC), or Urothelial Carcinoma (UC): Phase 1a Results","volume":"34","author":"Bendell","year":"2016","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-Related Adverse Events Associated With Immune Checkpoint Blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3779\/j.issn.1009-3419.2019.10.10","article-title":"Clinical Diagnosis and Treatment of Immune-Related Adverse Events in Digestive System Related to Immune Checkpoint Inhibitors","volume":"22","author":"Li","year":"2019","journal-title":"Zhongguo Fei Ai Za Zhi"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/his.14029","article-title":"Morphological Spectrum of Immune Check-Point Inhibitor Therapy-Associated Gastritis","volume":"76","author":"Johncilla","year":"2020","journal-title":"Histopathology"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/his.13963","article-title":"Immune-Related Adverse Events in the Gastrointestinal Tract: Diagnostic Utility of Upper Gastrointestinal Biopsies","volume":"76","author":"Zhang","year":"2020","journal-title":"Histopathology"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.gie.2017.04.033","article-title":"Acute Hemorrhagic Gastritis After Nivolumab Treatment","volume":"86","author":"Kobayashi","year":"2017","journal-title":"Gastrointest Endosc"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.07.029","article-title":"Nivolumab-Associated Nausea and Vomiting as an Immune Adverse Event","volume":"84","author":"Shi","year":"2017","journal-title":"Eur J Cancer"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e57","DOI":"10.14309\/crj.2017.57","article-title":"Severe Esophagitis and Gastritis From Nivolumab Therapy","volume":"4","author":"Boike","year":"2017","journal-title":"ACG Case Rep J"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/rcr2.334","article-title":"Severe Upper Gastrointestinal Disorders in Pembrolizumab-Treated Non-Small Cell Lung Cancer Patient","volume":"6","author":"Onuki","year":"2018","journal-title":"Respirol Case Rep"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1159\/000491862","article-title":"Severe Gastritis After Administration of Nivolumab and Ipilimumab","volume":"11","author":"Nishimura","year":"2018","journal-title":"Case Rep Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1415675112","article-title":"Th17 Cells Give Rise to Th1 Cells That Are Required for the Pathogenesis of Colitis","volume":"112","author":"Harbour","year":"2015","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.840916\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T10:00:37Z","timestamp":1654250437000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.840916\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,3]]},"references-count":23,"alternative-id":["10.3389\/fimmu.2022.840916"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.840916","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,3]]},"article-number":"840916"}}